skip to Main Content

Board of Directors

Alimera eyecon reverse color
Adam Morgan
Chairman of the Board, Alimera Sciences and Chief Investment Officer, Velan Capital Investment Management LP

Adam Morgan has been a member of the board of directors since March 2023 and was named Chairman in August of 2023. He currently serves as the Chief Investment Officer of Velan Capital Investment Management LP, a healthcare-dedicated investment firm based in Alpharetta, Georgia. Mr. Morgan also currently serves on the board of directors of Health Outlook Corporation, a privately-held developer of predictive healthcare technology and service based in New York, New York, where he serves as a director and chair of the company’s audit committee, and Heron Therapeutics, Inc., a publicly-listed biotechnology company focused on advancing the standard of care for acute and oncology patients, where he serves as a director and member of the nomination and governance committee. Mr. Morgan received his B.S. in chemistry from the University of Minnesota and his M.B.A. from the Carlson School of Management at the University of Minnesota.

Rick Eiswirth
President and Chief Executive Officer, Alimera Sciences

Richard S. Eiswirth, Jr. has been President and Chief Executive Officer since January 2019. Mr. Eiswirth previously served as President and Chief Financial Officer of our Company since January 2016; our Chief Operating Officer and Chief Financial Officer from August 2010 until December 2015 and as our Chief Financial Officer from October 2005 to August 2010. From 2003 to 2005, Mr. Eiswirth served as founding partner of Brand Ignition Group, engaged in consumer products acquisition activities. From 2002 to 2005, Mr. Eiswirth served as President of Black River Holdings, Inc., a financial consultancy he founded in 2002. Mr. Eiswirth served as Chief Financial Officer and Senior Executive Vice President of Netzee, Inc., a provider of Internet banking solutions to community banks from 1999 to 2002. Mr. Eiswirth held various positions with Arthur Andersen, where he began his career, from 1991 to 1999. Mr. Eiswirth served as a director of Celtaxsys Inc., a privately held biotechnology company, where he also chairs the audit committee. Mr. Eiswirth previously served as chairman, audit committee chairman and member of the compensation committee of Jones Soda Co., a Seattle, Washington based beverage company, and as director and audit committee chairman of Color Imaging, Inc., a Norcross, Georgia based manufacturer of printer and copier supplies. Mr. Eiswirth was previously a Certified Public Accountant in Georgia. Mr. Eiswirth holds a B.A. in accounting from Wake Forest University.

Ross DeMont
Chief Investment Officer, The Rainin Group, Inc.

Ross Demont has been a member of the board of directors since August 2023. He is currently Chief Investment Officer at the Rainin Group, Inc., which manages the assets of both a family office and the investments of the Kenneth Rainin Foundation. Previously, Mr. DeMont was a Managing Member and Portfolio Manager of Midwood Capital Management, a private investment partnership that made concentrated investments in public companies. Mr. DeMont has also worked as an Associate at Igoe Capital Partners, at Presidio Strategies LLC. in Mergers and Acquisitions and at JP Morgan with a focus on Corporate Finance and Mergers and Acquisitions. He has also served on multiple Boards of Directors. Mr. DeMont graduated from Connecticut College with a BA in both Economics and Government and earned an MBA from The Tuck School of Business at Dartmouth.

Michael Kaseta
Chief Financial Officer, Liquidia Corporation

Michael Kaseta has been a member of the board of directors since March 2023. Since December 2020 has held the role of Chief Financial Officer (CFO) at Liquidia. Mr. Kaseta has previously held CFO positions at Aerami Therapeutics, Aralez Pharmaceuticals and Sanofi where he spent eleven years in a variety of financial roles before being appointed CFO at Sanofi SA for North America Global Services and the North America Pharmaceutical Region. Mr. Kaseta holds a BBA in accounting from James Madison University and is a CPA (inactive) licensed in the state of New Jersey.

Erin Parsons
President, Parsons Medical Communications

Erin Parsons has been a member of our board of directors since December 2021. Ms. Parsons has more than 20 years of experience working in the ophthalmic industry overseeing scientific strategy, medical communications, advocacy development, and peer-to-peer educational programs, much of this in the retina space. She founded the eyecare-only medical strategy and communications company, Parsons Medical Communications (PMC). Ms. Parsons is a respected and highly sought-after ophthalmic industry veteran based in Boston, MA with wide-ranging experience in eyecare including nearly every major disease state of the eye. She was involved in the launch of LUCENTIS® (Roche/Genentech) and has experience with other retina products and programs including Syfovre™ for geographic atrophy (Apellis); OTT166, an investigational topical integrin inhibitor for diabetic retinopathy (OcuTerra); Encapsulated Cell Therapy for retina disease (Neurotech); ForeseeHome® monitoring device (Notal Vision); antisense oligonucleotide gene therapy (Wave Therapeutics); and BEOVU® and TRIESENCE® for retinal disease (Novartis). Ms. Parsons is an independent director for Kiora Pharmaceuticals and is engaged with various associations in the eyecare space including Ophthalmic World Leaders (OWL), the Ophthalmology Innovation Summit (where she led a Masterclass on KOL Advocacy), and The Holland Foundation for Sight Restoration. Ms. Parsons received a BS in Biology from Wake Forest University.

Maggie A. Pax
Board Member (Life Sciences)

Maggie Pax has been a member of the board of directors since November 2023. She is currently serving as a board member for Jellagen Ltd., a privately-held company developing and manufacturing tissue engineering and biomaterials products. She is also on the board of BioPorto, Inc., a wholly-owned U.S. subsidiary of a Denmark-listed in-vitro diagnostics innovator developing biomarkers for kidney disease. Previously, Ms. Pax was a senior executive at Thermo-Fisher from 2012 to 2020 where her latest role was as Vice President, Strategy and Innovation, Clinical Supply Chain / Pharma Services. Previously, she served as Vice President, Business and Clinical Development with Microchips BioMedical, a drug delivery company, and Vice President, Business Development for CareScout, a healthcare services company acquired by Genworth. She began her career at Phillips Healthcare where she held senior leadership roles in business development, marketing, and product management from 1989 – 2000. Ms. Pax holds an MBA from the Harvard Business School and is a board director of the Harvard Business School Healthcare Alumni Association.

Peter J. Pizzo, III
Chief Financial Officer, Intrinsic Therapeutics, Inc.

Peter J. Pizzo, III has been a member of our board of directors since 2010. Mr. Pizzo currently serves as Chief Financial Officer of Intrinsic Therapeutics, Inc., a private medical device company that has developed and is commercializing a product to prevent reherniation and reoperation following lumbar discectomy surgery.  Prior to joining Intrinsic, Mr. Pizzo served as Chief Financial Officer of several private medical device companies, including ControlRad, Inc., Cartiva, Inc., Carticept Medical, Inc. and Proxima Therapeutics, Inc. From 1996 to 2001, Mr. Pizzo worked for Serologicals Corporation, a publicly traded provider of biological products to life science companies, ultimately serving as Chief Financial Officer. From 1995 to 1996, Mr. Pizzo served as Vice President and Controller of ValueMark Healthcare Systems, Inc., a privately held owner-operator of psychiatric hospitals and from 1992 until 1995, in various senior financial positions at Hallmark Healthcare Corporation, a publicly traded hospital management company, most recently as Treasurer. Mr. Pizzo holds a Bachelor of Science with Special Attainments in Commerce from Washington and Lee University. Mr. Pizzo is an “audit committee financial expert” as that term is defined in the rules and regulations of the SEC.

John Snisarenko
Independent Director, Advisor and Board Member (Ophthalmic Therapeutic Area)

John Snisarenko has been a member of our board of directors since July 2019. Mr. Snisarenko has 35 years of commercial experience in the pharmaceutical industry, including major retina and ophthalmology businesses. Mr. Snisarenko’s most recent position was Chief Commercial Officer for Oyster Point Pharma where he lead the launch planning, infrastructure build and commercial launch for Tyrvava®. Mr. Snisarenko was Group Vice President and Head of the Ophthalmics franchise at Shire (now Takeda) where he commercialized Xiidra®. Prior to joining Shire, Mr. Snisarenko led commercial activities for Genentech’s ophthalmology (Lucentis®) and rheumatology (Rituxan®, Actemra®) franchises for 10 years. Mr. Snisarenko also held various positions of increasing responsibility at CIBA Vision/Novartis Pharma Canada. Mr. Snisarenko has held numerous advisory board positions and was a board member for the Foundation Fighting Blindness in Canada. He holds a B.Sc. in Biochemistry and an MBA in Marketing and International Business from McGill University in Montreal, Canada.

Back To Top
Skip to content